VEGFA and neoplasm: In separate studies (not shown), no WT or CD200R1KO mice survived following treatment with surgery and anti-VEGF alone, and survival with paclitaxil as the sole chemotherapeutic agent was ≤50% of that seen using the combination shown, in both CD200R1KO and WT mice with each tumor used.